Literature DB >> 6999846

Tumoural antigens on experimental and human glioblastoma.

J E Roda, J J Heredero, F J Villarejo, J M Roda.   

Abstract

The fact that glioblastoma multiforme possesses antigens differing from those of normal brain has been stressed in early papers from Scheimberg, Mahaley, Eggers, and Brooks. In our work the presence of specific cytoplasmic and nuclear antigens in neoplastic cells has been demonstrated. These specific antigens are present not only in experimental tumours from the rat, but also in human glioblastoma, and are easily demonstrated by immunodiffusion and immunofluorescence techniques. From our work differences between intracellular and membrane antigens are clear, as the latter do not react with IgG immunoglobulin. On the other hand, tumoural antigens in glioblastoma have similar antigenic qualities to those of histocompatible antigens in normal brain. Experimental and human glioblastomas have weak antigens, as demonstrated by frequent tumour recurrence following amputation and the positive cross-reaction of antibody with normal brain in experimental models. Glioblastoma multiforme may have a common antigen as its antibodies easily cross-react positively with different human tumours with similar, histological features. As tumoural membranes did not react as cytoplasm and nuclei, we cannot say that membrane antigens resemble those of intracellular contents. The fact that viral-induced tumours may have common antigens should point to aetiological possibilities in this group of tumours. Delayed cellular response is very useful during the follow-up of these patients. Positive DNCB and intradermal reactions could be elicited in those patients in whom the antigenic overload has been reduced as a consequence of a surgical procedure. On the other hand, patients with extensive and infiltrating tumoural masses exhibited weak or negative delayed cellular responses. Humoral responses from the patient's sera may not have the prognostic value of cellular responses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6999846     DOI: 10.1007/bf02074792

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  20 in total

1.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

Review 2.  Combined modality therapy for intracranial tumors.

Authors:  H J Bloom
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

3.  Ultra-rapid fluorescent labelling of proteins.

Authors:  H RINDERKNECHT
Journal:  Nature       Date:  1962-01-13       Impact factor: 49.962

4.  Autoradiographic and fluorescence antibody studies of the human host immune response to gliomas.

Authors:  A E Eggers
Journal:  Neurology       Date:  1972-03       Impact factor: 9.910

5.  Demonstration of cell-mediated immunity to human neoplasms of various histological types.

Authors:  I Hellström; K E Hellström; H O Sjögren; G A Warner
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

6.  Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines.

Authors:  G Klein; E Klein; P Clifford
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

7.  Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas.

Authors:  I Hellström; K E Hellström
Journal:  Int J Cancer       Date:  1970-03-15       Impact factor: 7.396

8.  Heterologous antibodies in human and rat's glioblastoma.

Authors:  J E Roda; F Villarejo; J Heredero; S Obrador
Journal:  Acta Neurochir (Wien)       Date:  1976       Impact factor: 2.216

9.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

10.  Antigens in human glioblastomas and meningiomas: Search for tumour and onco-foetal antigens. Estimation of S-100 and GFA protein.

Authors:  L Dittmann; N H Axelsen; B Norgaard-Pedersen; E Bock
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.